Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR21Q3)

Drug Name

Clevudine Drug Info

Synonyms

Clevudine; 163252-36-6; Levovir; L-FMAU; UNII-IN51MVP5F1; Clevudine (Levovir); IN51MVP5F1; 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)thymine; 1-((2S,3R,4S,5S)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; AK106264; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; Clevudine [USAN:INN]; Revovir; Clevudine (USAN)

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B	1E51	Phase 4	[1]
Hepatitis B virus infection	1E51.0	Phase 3	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]

Cross-matching ID

PubChem CID: 73115
ChEBI ID: CHEBI:135964
CAS Number: CAS 163252-36-6
TTD Drug ID: DMR21Q3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hepatitis B virus Reverse transcriptase (HBV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[4]
LB80380	DMJM9LZ	Hepatitis B virus infection	1E51.0	Phase 2b	[5]
Pradefovir	DM1O0DV	Hepatitis virus infection	1E50-1E51	Phase 2	[6]
MIV-210	DM2NF6X	Hepatitis B virus infection	1E51.0	Phase 2	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis B virus Reverse transcriptase (HBV RT)	TTS5K1M	DPOL_HBVA3	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00501124) Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV. U.S. National Institutes of Health.
2	2011 Pipeline of Bukwang.
3	ClinicalTrials.gov (NCT04347915) The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. U.S. National Institutes of Health.
4	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7.
5	2011 Pipeline of LG Life Sciences.
6	DOI: 10.1128/AAC.01566-05
7	Emerging antivirals for the treatment of hepatitis B